Summary:
- This article discusses the development of a new COVID-19 vaccine candidate called EXS-21501, which is being developed by the Israeli company Enlivex Therapeutics.
- The vaccine is designed to stimulate the immune system to fight the SARS-CoV-2 virus, which causes COVID-19, and has shown promising results in early clinical trials.
- The article explains that the vaccine is unique in its approach, as it aims to regulate the immune system's response to the virus, rather than just targeting the virus itself, which could lead to a more effective and long-lasting immune response.